Jeng-Feng Lin1, Shun-Yi Hsu1, Ming-Sheng Teng2, Semon Wu3, Chien-An Hsieh2, Shih-Jung Jang2, Chih-Jen Liu2, Hsuan-Li Huang2, Yu-Lin Ko1. 1. Division of Cardiology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City; ; School of Medicine, Tzu Chi University, Hualien; 2. Division of Cardiology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City; 3. Division of Cardiology, Department of Internal Medicine, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City; ; Department of Life Science, Chinese Culture University, Taipei, Taiwan.
Abstract
BACKGROUND: Activin A levels increase in a variety of heart diseases including ST-elevation myocardial infarction (STEMI). The aim of this study is to investigate whether the level of activin A can be beneficial in predicting left ventricular remodeling, heart failure, and death in patients with ST-elevation myocardial infarction (STEMI). METHODS: We enrolled 278 patients with STEMI who had their activin A levels measured on day 2 of hospitalization. Echocardiographic studies were performed at baseline and were repeated 6 months later. Thereafter, the clinical events of these patients were followed for a maximum of 3 years, including all-cause death and readmission for heart failure. RESULTS: During hospitalization, higher activin A level was associated with higher triglyceride level, lower left ventricular ejection fraction (LVEF), and lower left ventricular end diastolic ventricular volume index (LVEDVI) in multivariable linear regression model. During follow-up, patients with activin A levels > 129 pg/ml had significantly lower LVEF, and higher LVEDVI at 6 months. Kaplan-Meier survival curves showed that activin A level > 129 pg/ml was a predictor of all-cause death (p = 0.022), but not a predictor of heart failure (p = 0.767). CONCLUSIONS: Activin A level > 129 pg/ml predicts worse left ventricular remodeling and all-cause death in STEMI.
BACKGROUND: Activin A levels increase in a variety of heart diseases including ST-elevation myocardial infarction (STEMI). The aim of this study is to investigate whether the level of activin A can be beneficial in predicting left ventricular remodeling, heart failure, and death in patients with ST-elevation myocardial infarction (STEMI). METHODS: We enrolled 278 patients with STEMI who had their activin A levels measured on day 2 of hospitalization. Echocardiographic studies were performed at baseline and were repeated 6 months later. Thereafter, the clinical events of these patients were followed for a maximum of 3 years, including all-cause death and readmission for heart failure. RESULTS: During hospitalization, higher activin A level was associated with higher triglyceride level, lower left ventricular ejection fraction (LVEF), and lower left ventricular end diastolic ventricular volume index (LVEDVI) in multivariable linear regression model. During follow-up, patients with activin A levels > 129 pg/ml had significantly lower LVEF, and higher LVEDVI at 6 months. Kaplan-Meier survival curves showed that activin A level > 129 pg/ml was a predictor of all-cause death (p = 0.022), but not a predictor of heart failure (p = 0.767). CONCLUSIONS: Activin A level > 129 pg/ml predicts worse left ventricular remodeling and all-cause death in STEMI.
Entities:
Keywords:
Activin A; Acute myocardial infarction; Left ventricular remodeling
Authors: Kristian L Jones; Ashley Mansell; Shane Patella; Bernadette J Scott; Mark P Hedger; David M de Kretser; David J Phillips Journal: Proc Natl Acad Sci U S A Date: 2007-10-02 Impact factor: 11.205
Authors: M A Engelse; J M Neele; T A van Achterberg; B E van Aken; R H van Schaik; H Pannekoek; C J de Vries Journal: Circ Res Date: 1999-11-12 Impact factor: 17.367
Authors: M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman Journal: Circulation Date: 1994-01 Impact factor: 29.690
Authors: Michel G Khouri; Ronald M Peshock; Colby R Ayers; James A de Lemos; Mark H Drazner Journal: Circ Cardiovasc Imaging Date: 2010-01-08 Impact factor: 7.792
Authors: Estibaliz Castillero; Hirokazu Akashi; Marc Najjar; Ruiping Ji; Lea Maria Brandstetter; Catherine Wang; Xianghai Liao; Xiaokan Zhang; Alexandra Sperry; Marcia Gailes; Karina Guaman; Adam Recht; Ira Schlosberg; H Lee Sweeney; Ziad A Ali; Shunichi Homma; Paolo C Colombo; Giovanni Ferrari; P Christian Schulze; Isaac George Journal: Am J Physiol Heart Circ Physiol Date: 2019-12-30 Impact factor: 4.733